Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GRID1 antisense RNA 1 (GRID1-AS1) is a long non-coding RNA (lncRNA) transcribed antisense to the GRID1 gene, which encodes a neuronal glutamate receptor subunit. GRID1-AS1 can regulate the expression of GRID1 and potentially other genes, typically by mechanisms involving transcriptional interference or RNA-RNA interactions. Antisense lncRNAs are known to participate in processes such as modulating mRNA abundance, chromatin structure, and epigenetic regulation. Although not a classical drug target, GRID1-AS1 may play roles in brain function and disease by influencing GRID1 gene expression and other pathways[3][6][8]. GRID1 antisense RNA 1 is specifically annotated as a long noncoding RNA, with mechanistic functions inferred from the general biology of antisense RNAs, including gene regulation, epigenetic modulation, and control of cellular phenotype[4][5][8]. Evidence for direct association with disease or drug development is currently lacking.
No known drugs; general mechanism for antisense RNA-based approaches involve antisense oligonucleotides silencing target RNAs, gene activation or repression, or modification of chromatin and transcriptional machinery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GRID1 antisense RNA 1 (GRID1-AS1).